MedPath

Commons, Marty

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Phase 1
Completed
Conditions
Solid Tumors
Hepatic Impairment
Interventions
First Posted Date
2011-09-29
Last Posted Date
2020-12-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
38
Registration Number
NCT01443481
Locations
πŸ‡ΊπŸ‡Έ

University of California at Los Angeles Dept. of UCLA (4), Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Duke University Medical Center DUMC, Durham, North Carolina, United States

πŸ‡ΊπŸ‡Έ

Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, United States

and more 1 locations

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

Phase 1
Completed
Conditions
Mild Moderate
or Severe Renal Impairment
Interventions
First Posted Date
2011-09-28
Last Posted Date
2020-12-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
48
Registration Number
NCT01442259
Locations
πŸ‡©πŸ‡ͺ

Novartis Investigative Site, Kiel, Germany

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Completed
Conditions
Multiple Sclerosis
Interventions
Drug: other disease-modifying therapy
First Posted Date
2011-09-28
Last Posted Date
2022-01-14
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
3076
Registration Number
NCT01442194
Locations
πŸ‡΅πŸ‡·

Novartis Investigative Site, San Juan, Puerto Rico

Sickle Cell Disease: A Retrospective Chart Review

Completed
Conditions
Sickle Cell Anemia
First Posted Date
2011-09-27
Last Posted Date
2012-10-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
261
Registration Number
NCT01441375
Locations
πŸ‡ΊπŸ‡Έ

Tulane University, New Orleans, Louisiana, United States

πŸ‡ΊπŸ‡Έ

Universit of Tennessee, Memphis, Tennessee, United States

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Thrombocytopaenia
Interventions
Drug: placebo
First Posted Date
2011-09-26
Last Posted Date
2017-06-05
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
162
Registration Number
NCT01440374
Locations
πŸ‡ΉπŸ‡­

Novartis Investigative Site, Songkla, Thailand

Dose Finding Study for QAW039 in Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
First Posted Date
2011-09-21
Last Posted Date
2020-12-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
1043
Registration Number
NCT01437735
Locations
πŸ‡¬πŸ‡§

Novartis Investigative Site, Glasgow - Scotland, United Kingdom

Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

Phase 4
Terminated
Conditions
Depression
Relapsing-remitting Multiple Sclerosis
Interventions
First Posted Date
2011-09-20
Last Posted Date
2014-09-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
54
Registration Number
NCT01436643
Locations
πŸ‡©πŸ‡ͺ

Novartis Investigative Site, Zwickau, Germany

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

Phase 1
Completed
Conditions
Insulin Resistance
Interventions
Drug: Placebo
First Posted Date
2011-09-16
Last Posted Date
2015-04-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
43
Registration Number
NCT01435330
Locations
πŸ‡ΊπŸ‡Έ

Novartis Investigative Site, Tacoma, Washington, United States

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: RLX030A
First Posted Date
2011-09-14
Last Posted Date
2020-12-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
55
Registration Number
NCT01433458
Locations
πŸ‡·πŸ‡Ί

Novartis Investigative Site, Moscow, Russian Federation

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Phase 1
Completed
Conditions
Post Polycythemia-Vera Myelofibrosis
Idiopathic Myelofibrosis
Post Essential Thrombocythemia Myelofibrosis
Interventions
First Posted Date
2011-09-14
Last Posted Date
2021-06-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
61
Registration Number
NCT01433445
Locations
πŸ‡¬πŸ‡§

Novartis Investigative Site, London, United Kingdom

Β© Copyright 2025. All Rights Reserved by MedPath